Xcell Therapeutics Inc. announced that it has received KRW 19.9 billion in Series C round of funding on March 18, 2021. The transaction included participation from Korea Development Bank, Investment Arm, Log Investment, Korea Asset Investment Securities Co., Ltd., Investment Arm, HB Investment, Inc., Yuanta Investment, SBI Investment KOREA Co., Ltd. (KOSDAQ:A019550), APR Partners and new investor Daishin Securities Co. Ltd., Investment Arm. The company has raised KRW 33.7 billion in funding till date.